Tetrahalogenated compounds useful as inhibitors of angiogenesis

US8143252B2 · kind B2 · utility

Assignee

• The United States of America as Represented by the Secretary of the Department of Health and Human Services · US

Inventors

• William D. Figg · Fairfax, US
• Erin Gardner · Fairfax, US
• Michael Gutschow · Leipzig, DE
• Agnieszka Ambrozak · Buchs, CH

Key dates

• Filing date: Oct 10, 2008
• Grant date: Mar 27, 2012
• Expiry date: Sep 23, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D403/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Methods for inhibiting a neoplasm in a subject and methods of inhibiting undesired angiogenesis that include administering to a subject a therapeutically effective amount of at least one novel tetrahalogenated compound, or a pharmaceutically acceptable salt thereof.